E., Amato, A., Bozzolo, H., Hollway, J., Cook, A., Ramadan, Y., Crowl, L., Zhang, D., Thompson, S., Testa, G., Kliewer, V., Wigal, T., McBurnett, K., and Manos, M
Baseline ALT and AST before starting either agent is reasonable clinical practice, with repeat testing at 3 months if any hepatic risk factors exist
The proposal is straightforward: Move toward biomarker-driven patient stratification Design more flexible, biology-informed clinical trials Align regulatory approaches with what already works in oncology and dementia Dementia offers a useful reference point
Enamel mineral content in patients with severe tooth wear
34 HeX.PengX.ZhangS.YangT.HuoJ.ZhangY
I: Protective effect of melatonin and butylhydroxytoluene on sperm function